Aetna modified CPB 0577 covering laser treatment for psoriasis and selected skin conditions, effective October 2, 2025. Here's what billing teams need to know before submitting claims.
Aetna, a CVS Health company, updated this coverage policy to define medical necessity criteria for excimer and pulsed dye laser procedures billed under CPT 96920, 96921, and 96922, along with laser hair removal and laser treatment for acne keloidalis nuchae and penile intraepithelial neoplasia. The change tightens the step therapy requirements for psoriasis laser billing and sets hard limits on treatment frequency — up to 13 sessions per course and three courses per year. If your dermatology or urology billing team submits these claims for Aetna members, this policy revision directly affects your reimbursement.
Quick-Reference: Aetna CPB 0577 Laser Skin Treatment Policy Change 2025
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Laser Treatment for Psoriasis and Other Selected Skin Conditions |
| Policy Code | CPB 0577 |
| Change Type | Modified |
| Effective Date | October 2, 2025 |
| Impact Level | High |
| Specialties Affected | Dermatology, Urology, Plastic Surgery, Primary Care (with skin condition billing) |
| Key Action | Audit psoriasis laser claims for step therapy documentation — at least three topical agents for three or more months — before submitting CPT 96920, 96921, or 96922 |
Aetna Laser Psoriasis Coverage Criteria and Medical Necessity Requirements 2025
The core of this coverage policy is a step therapy wall. Aetna will not consider laser treatment medically necessary for psoriasis unless the patient has failed three or more months of topical treatment — and that treatment must include at least three specific agents from a defined list.
Those agents are anthralin, corticosteroids (such as betamethasone dipropionate ointment or fluocinonide cream), keratolytic agents (such as lactic acid, salicylic acid, or urea), retinoids (such as tazarotene), tar preparations, and vitamin D derivatives (such as calcipotriene). Your documentation needs to show the patient tried at least three of these. Without that, expect a claim denial.
The patient's psoriasis also must be mild-to-moderate and localized, affecting 10% or less of their body surface area. This is not the right pathway for widespread disease.
Once laser treatment starts, Aetna caps coverage at 13 treatments per course. After that course ends, if the patient does not show a measurable response — documented by a reduction in PASI score or another objective measure — Aetna will not cover additional courses. The policy allows up to three courses per year, but only if the patient demonstrates clinical improvement. That's a meaningful distinction. Don't assume subsequent courses are automatically covered.
For laser psoriasis billing under CPT 96920 (total area less than 250 sq cm), CPT 96921 (250–500 sq cm), or CPT 96922 (over 500 sq cm), the area of treatment determines which code you bill. Make sure your documentation matches the treatment area documented in the clinical note.
Prior authorization requirements are not explicitly detailed in the CPB 0577 policy language, but given the step therapy criteria and frequency limits, document everything before you submit. If your practice does not already collect a topical therapy failure history before scheduling laser sessions, start that workflow now — before the October 2, 2025 effective date.
Aetna Laser Skin Treatment Exclusions and Non-Covered Indications
Several codes appear on Aetna's explicit non-covered list under CPB 0577. Low-level laser therapy billed under CPT 0552T or HCPCS S8948 is not covered for any indication listed in this policy. That's worth a direct call-out: some practices bill low-level laser for inflammatory skin conditions thinking it falls under a broader phototherapy umbrella. It does not.
CPT codes 17000 through 17004 — the destruction series for benign and premalignant lesions — are also not covered under this policy for these indications. The same applies to the malignant lesion destruction series: CPT 17270 through 17276. If your team has been using any of these codes for laser-based psoriasis treatment, that's a problem. Those codes map to a different clinical scenario.
The takeaway: if you're not billing CPT 96920, 96921, 96922, 17110, 17111, or 17380 — depending on the specific indication — look hard at your code selection before the claim goes out.
Coverage Indications at a Glance
| Indication | Status | Relevant CPT Codes | Notes |
|---|---|---|---|
| Mild-to-moderate localized plaque psoriasis (≤10% BSA) — excimer or pulsed dye laser | Covered | 96920, 96921, 96922 | Must fail ≥3 topical agents for ≥3 months; max 13 treatments/course, 3 courses/year; PASI or objective response required to continue |
| Recurrent pilonidal cyst — laser hair removal | Covered | 17380 | Medical necessity criteria apply |
| Acne keloidalis nuchae (AKN) — laser excision for extensive scarring (plaque or tumor stage) | Covered | 17110, 17111 | For extensive scarring only |
| Acne keloidalis nuchae (AKN) — laser depilation for active disease poorly responsive to medical therapy | Covered | 17380 | Must show poor response to oral/topical antibiotics and intralesional steroids |
| Penile intraepithelial neoplasia — laser treatment | Covered | 17110, 17111 | Medical necessity documentation required |
| Vitiligo — excimer laser | Not covered under this policy | — | See CPB 0422 |
| Low-level laser therapy | Not Covered | 0552T, S8948 | Not covered for any indication in CPB 0577 |
| Destruction of benign/premalignant lesions | Not Covered | 17000–17004 | Not covered for indications listed in CPB 0577 |
| Destruction of malignant lesions | Not Covered | 17270–17276 | Not covered for indications listed in CPB 0577 |
Aetna Laser Skin Treatment Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your psoriasis laser documentation before October 2, 2025. Review every active patient scheduled for excimer or pulsed dye laser treatment. Confirm their chart shows at least three months of topical therapy failure across at least three of the six specified agents. If that documentation is missing, the claim will not survive a review. |
| 2 | Build a topical therapy failure checklist into your intake workflow. Your clinical staff need to capture anthralin, corticosteroid, keratolytic, retinoid, tar, and vitamin D derivative history before the first laser session. A structured intake form is the easiest way to do this. Don't leave it to free-text notes. |
| 3 | Confirm body surface area is documented before selecting CPT 96920, 96921, or 96922. The code you bill is determined by treatment area in square centimeters. If the dermatologist's note says "localized psoriasis" without measuring the area, you do not have enough to code this correctly. |
| 4 | Track PASI scores or equivalent objective measures for every course of treatment. Aetna requires documented clinical response to authorize additional courses. If the patient does not improve after the first course, additional laser billing will not meet medical necessity. Document the PASI score at baseline and at the end of each course. |
| 5 | Remove CPT 0552T and HCPCS S8948 from any laser skin treatment charge capture templates. These codes are not covered under this policy. If your charge capture system has a laser treatment order set that bundles these in, update it now. |
| 6 | Confirm code selection for AKN cases. Laser excision for plaque or tumor stage AKN bills under CPT 17110 or 17111. Laser hair removal for active AKN that has failed antibiotics and intralesional steroids bills under CPT 17380. These are different procedures with different documentation requirements. Don't mix them up. |
| 7 | Route vitiligo cases to CPB 0422, not CPB 0577. Aetna explicitly directs excimer laser for vitiligo to a separate policy. If your billing team references CPB 0577 for vitiligo claims, that's an error. Update your internal policy reference documents. |
If you're unsure how this policy applies to your specific patient mix or specialty billing setup, talk to your compliance officer before the October 2, 2025 effective date.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Laser Skin Treatment Under CPB 0577
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 17110 | CPT | Destruction of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions |
| 17111 | CPT | Destruction of benign lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions |
| 17380 | CPT | Electrolysis epilation, each 30 minutes (laser hair removal) |
| 96920 | CPT | Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm |
| 96921 | CPT | Laser treatment for inflammatory skin disease (psoriasis); 250 sq cm to 500 sq cm |
| 96922 | CPT | Laser treatment for inflammatory skin disease (psoriasis); over 500 sq cm |
Not Covered CPT and HCPCS Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 0552T | CPT | Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional | Not covered for indications listed in CPB 0577 |
| 17000 | CPT | Destruction of premalignant lesion, first lesion | Not covered for indications listed in CPB 0577 |
| 17001 | CPT | Destruction of premalignant lesions, second through 14 lesions, each | Not covered for indications listed in CPB 0577 |
| 17002 | CPT | Destruction of premalignant lesions, 15 or more lesions | Not covered for indications listed in CPB 0577 |
| 17003 | CPT | Destruction of premalignant lesion, each additional lesion (List separately in addition to code for first lesion) | Not covered for indications listed in CPB 0577 |
| 17004 | CPT | Destruction of premalignant lesions, 15 or more lesions | Not covered for indications listed in CPB 0577 |
| 17270 | CPT | Destruction, malignant lesion, any method; trunk, arms or legs; lesion diameter 0.5 cm or less | Not covered for indications listed in CPB 0577 |
| 17271 | CPT | Destruction, malignant lesion, any method; trunk, arms or legs; lesion diameter 0.6 to 1.0 cm | Not covered for indications listed in CPB 0577 |
| 17272 | CPT | Destruction, malignant lesion, any method; trunk, arms or legs; lesion diameter 1.1 to 2.0 cm | Not covered for indications listed in CPB 0577 |
| 17273 | CPT | Destruction, malignant lesion, any method; trunk, arms or legs; lesion diameter 2.1 to 3.0 cm | Not covered for indications listed in CPB 0577 |
| 17274 | CPT | Destruction, malignant lesion, any method; trunk, arms or legs; lesion diameter 3.1 to 4.0 cm | Not covered for indications listed in CPB 0577 |
| 17275 | CPT | Destruction, malignant lesion, any method; trunk, arms or legs; lesion diameter over 4.0 cm | Not covered for indications listed in CPB 0577 |
| 17276 | CPT | Destruction, malignant lesion, any method; scalp, neck, hands, feet, genitalia; lesion diameter 0.5 cm or less | Not covered for indications listed in CPB 0577 |
| S8948 | HCPCS | Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser | Not covered for indications listed in CPB 0577 |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| B00.1 | Herpesviral vesicular dermatitis |
| B07.8 | Other viral warts (facial warts) |
| B35.1 | Tinea unguium |
| C76.8 | Malignant neoplasm of other specified ill-defined sites (nail tumor) |
| C79.89 | Secondary malignant neoplasm of other specified sites (nail tumor) |
| C84.0–C84.9 | Mycosis fungoides (multiple subcategories) |
| D07.1 | Carcinoma in situ of vulva |
| D21.9 | Benign neoplasm of connective and other soft tissue, unspecified (nail tumor) |
| D23.0–D23.9 | Other benign neoplasms of skin (hidrocystomas) |
| D29.0 | Benign neoplasm of penis (penile intraepithelial neoplasia) |
| D36.7 | Benign neoplasm of other specified sites (nail tumor) |
| D36.9 | Benign neoplasm, unspecified site (nail tumor) |
| D76.3 | Other histiocytosis syndromes (necrobiotic xanthogranuloma) |
| D86.0 | Sarcoidosis |
| E08.621–E08.628 | Diabetes with ulcer or other skin complications |
| E09.621–E09.628 | Diabetes with ulcer or other skin complications |
| E10.621–E10.628 | Diabetes with ulcer or other skin complications |
| E11.621–E11.628 | Diabetes with ulcer or other skin complications |
| E13.621–E13.628 | Diabetes with ulcer or other skin complications |
| E85.4 | Organ-limited amyloidosis (cutaneous amyloidosis) |
| L03.11–L03.17 | Cellulitis of finger (multiple subcategories) |
The full ICD-10-CM list in CPB 0577 contains 212 codes. The table above shows the key diagnostic categories most relevant to the covered indications. Review the full policy at Aetna CPB 0577 for the complete code set.
Get the Full Picture for CPT 96920
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.